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Abstract
Background: Bovine luteal parenchymal cells express class II major histocompatibility complex
(MHC) molecules and stimulate class II MHC-dependent activation of T cells in vitro. The ability of
a class II MHC-expressing cell type to elicit a response from T cells in vivo is also dependent on
expression of costimulatory molecules by the antigen presenting cell and delivery of a
costimulatory signal to the T cell. Whether bovine luteal parenchymal cells express costimulatory
molecules and can deliver the costimulatory signal is currently unknown.
Methods: Bovine luteal tissue was collected during the early (day 5; day of estrus = day 0), mid
(day 11–12), or late (day 18) luteal phase of the estrous cycle, and at 0, 0.5, 1, 4, 12 or 24 hours
following administration of PGF2alpha to cows on day 10 of the estrous cycle. Northern analysis
was used to measure CD80 or CD86 mRNA concentrations in luteal tissue samples. Mixed luteal
parenchymal cell cultures and purified luteal endothelial cell cultures were prepared, and real-time
RT-PCR was used to examine the presence of CD80 and CD86 mRNA in each culture type.
Monoclonal antibodies to CD80 and CD86 were added to a mixed luteal parenchymal cell-T cell
co-culture in vitro T cell proliferation assay to assess the functional significance of costimulatory
molecules on activation of T lymphocytes by luteal parenchymal cells.
Results: Northern analysis revealed CD80 and CD86 mRNAs in luteal tissue, with greatest steady-
state concentrations at midcycle. CD80 and CD86 mRNAs were detected in mixed luteal
parenchymal cell cultures, but only slight amounts of CD80 (and not CD86) mRNA were detected
in cultures of luteal endothelial cells. Luteinizing hormone, PGF2alpha and TNF-alpha were without
effect on concentrations of CD80 or CD86 mRNA in mixed luteal parenchymal cells cultures. Anti-
CD80 or anti-CD86 monoclonal antibodies inhibited T cell proliferation in the in vitro T cell
proliferation assay.
Conclusion: It can be concluded from this study that parenchymal cells within the bovine CL
express functional costimulatory molecules that facilitate interactions between with T cells, and
these components of the antigen presentation pathway are expressed maximally in the midcycle
CL.
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Background
The body of evidence implicating immune cells as regula-
tors of luteal function is expanding. Macrophages and T
lymphocytes are found in the corpus luteum (CL) of a
number of species [1-9], as is messenger RNA and protein
of several T cell-derived cytokines [5-10]. T cell cytokines
such as interleukin-1β (IL-1β), tumor necrosis factor-α
(TNF-α) and interferon-γ (IFN-γ) inhibit LH-stimulated
steroidogenesis and induce PGF2α production in cultures
of mixed luteal parenchymal cells [11-18]. Bovine luteal
parenchymal cells express both class I and II major histo-
compatibility complex (MHC) molecules [19,20], which
allow the cells to interact with CD8+ and CD4+ T lym-
phocytes, respectively. Expression of class II MHC in vivo
increases near the time of luteal regression and in
response to administration of a luteolytic dose of PGF2α
[20]. Bovine luteal parenchymal cells also stimulate class
II MHC-dependent proliferation of T lymphocytes in vitro
[21,22], indicating that the class II MHC molecules
expressed by luteal parenchymal cells are functional and
that these cells can act as antigen presenting cells.
Class II-dependent presentation of antigen to T cells
occurs via interaction of class II MHC molecules on the
antigen presenting cell surface with the T cell receptor for
antigen (TCR) on the T lymphocyte surface. With regard
to T cells, there are two possible outcomes of MHC-medi-
ated cellular interactions. In one instance, binding of
MHC molecules to the TCR can occur in the absence of
accompanying interactions between additional cell sur-
face molecules. In this case, an inactive state known as
anergy will be induced in the T cells [23-25]. Induction of
anergy is one means by which tolerance to antigens in
peripheral tissues is induced, thus avoiding an autoim-
mune response [26].
Alternatively, MHC-TCR ligation can occur in conjunction
with costimulation. Costimulation is dependent on bind-
ing of costimulatory molecules present on the antigen-
presenting cell to the lymphocyte receptor CD28. The two
primary costimulatory molecules are CD80 and CD86,
also referred to as B7-1 and B7-2 [27,28]. Binding of either
costimulatory molecule to CD28 promotes T cell survival
[29] and induces T cell activation and clonal expansion
[30-32]. Therefore, depending on the presence or absence
of costimulatory molecules on the antigen-presenting cell,
MHC-mediated interactions have distinct and vastly dif-
ferent consequences. The objective of these studies was to
determine whether luteal parenchymal cells express func-
tional costimulatory molecules in order to understand
whether the class II MHC-dependent interaction of luteal
parenchymal cells with T lymphocytes induces anergy or
activation of T cells.
Methods
Reagents
Powdered Ham's F-12 culture medium, gentamicin, fetal
bovine serum, E. coli DH5α chemically competent cells,
restriction enzymes and TRIzol Reagent were all pur-
chased from Gibco/Life Technologies (Grand Island, NY).
Recombinant murine TNF-α was purchased from Gibco/
Life Technologies and R & D Systems. Bovine luteinizing
hormone (LH; NIAMMD-bLH-4) was provided by the
National Hormone and Pituitary Program (Baltimore,
MD). Insulin-transferrin-selenium (ITS) premix was
obtained from Collaborative Research Products. Bovine
serum albumin (fraction V), prostaglandin (PG)F2α, and
N-(2-hydroxyethyl) piperazine-N'-2-ethanesulfonic acid
(HEPES) buffer were purchased from Sigma Chemical Co.
(St. Louis, MO). Type I collagenase was acquired from
Worthington Biochemical Corp. (Freehold, NJ). Sodium
dodecyl sulfate (SDS) and 3-(N-morpholino) propanesul-
fonic acid (MOPS) buffer were acquired from Amresco
(Solon, OH). Digoxigenin-labeled rNTP mix (10×), alka-
line-phosphatase-conjugated anti-digoxigenin Fab frag-
ments, CDP-Star chemiluminescent substrate, blocking
reagent, and ampicillin were purchased from Roche
Molecular Biochemicals (Mannheim, Germany). Recom-
binant RNasin, Moloney murine leukemia virus reverse
transcriptase, TaqBead FastStart polymerase, and T7 and
T3 RNA polymerases were purchased from Promega
(Madison, WI). Hybond N+ membranes were obtained
from Amersham Pharmacia Biotech (Piscataway, NJ). Tis-
sue culture flasks were from Corning (Corning, NY). All
other chemicals were purchased from Sigma Chemical
Co. or Fisher Scientific (Fair Lawn, NJ).
Animals and tissue collection
Corpora lutea collected from normally cycling, multipa-
rous, lactating dairy cows between three and six years of
age were used in the present study. Corpora lutea to be
used for RNA extraction for Northern analysis were cut
into four equal pieces, snap frozen in liquid nitrogen,
transported to the lab in liquid nitrogen, and stored at -
80°C until RNA extraction was performed. Corpora lutea
were collected at early (day 5, n = 4), mid (days 10–11; n
= 4) or late (day 18; n = 4) stages of the estrous cycle, or at
0.5 (n = 4), 1 (n = 4), 4 (n = 4), 12 (n = 4) or 24 (n = 4)
hours following i.m. administration of 25 mg of PGF2α
(Lutalyse; Pfizer, New York, NY) on day 10 of the estrous
cycle to induce luteal regression. In addition, lymph node
tissue (used as a positive control) and skeletal muscle tis-
sue (used as a negative control) were collected from cows
at slaughter, snap frozen in liquid nitrogen, and stored at
-80°C until RNA extraction.
Corpora lutea to be used for cell culture were removed on
day 10 of the estrous cycle, immediately placed in ice-cold
Ham's F-12 culture medium and transported to the labo-Reproductive Biology and Endocrinology 2007, 5:5 http://www.rbej.com/content/5/1/5
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ratory for dissociation. Handling of animals and surgical
procedures were carried out according to protocols
approved by the Institutional Laboratory Animal Care and
Use Committee of The Ohio State University.
Dissociation of corpora lutea and culture of mixed luteal 
parenchymal cells
Dissociation of corpora lutea was carried out according to
procedures described previously [33]. Cells derived from
simple dissociation and culture of corpora lutea are
referred to throughout as "mixed luteal parenchymal
cells" to indicate the likely presence of steroidogenic
luteal cells as well as some luteal endothelial cells in these
cultures. Cell culture was performed in a humidified
atmosphere of 5% CO2 in air at 37°C. Dispersed cells (4
× 106 cells/flask) were cultured in serum-coated 25 cm2
flasks in a total of 4 ml of Ham's F-12 containing insulin
(5 μg/ml), transferrin (5 μg/ml), selenium (5 ng/ml), gen-
tamicin (20 μg/ml), and LH (1 ng/ml). Cells were allowed
to adhere overnight, medium was replaced, and cultures
were treated with LH (10 ng/ml), TNF-α (50 ng/ml), or
PGF2α (10 ng/ml), in a 3 × 3 factorial arrangement, with
all treatments performed in duplicate. The experiment
was replicated a total of four times using CL from different
animals. Treatment concentrations used in this study have
been shown previously to affect function, viability, and
gene expression in cultures of bovine mixed luteal paren-
chymal cells [15,34-36]. Medium and treatments were
replaced after 24 hours. Total RNA was extracted from cul-
tured cells after 48 hours of culture.
Isolation and culture of purified luteal endothelial cells
Endothelial cells isolated from bovine CL collected during
early pregnancy were purchased from Cambrex Bio-
Science (BioWittaker, Walkersville, MD) as described pre-
viously [37-39]. These cells are referred to as "luteal
endothelial cells" throughout, to distinguish them from
cultures of mixed luteal parenchymal cells (see previous
section). In the present study, luteal endothelial cells from
frozen aliquots (passages 3–5) (5,000 cells/cm2) were cul-
tured in EGM-2MV media, as recommended by the sup-
plier with 3% fetal bovine serum (Cambrex Biosciences,
BioWhittaker, Inc., Walkersville, MD) in 60 mm dishes.
Cultures were maintained at 37°C in a humidified atmos-
phere of 5% CO2 and 95% air. Culture medium was
replaced every 48 hours until 80–90% confluent. On the
day of harvest, cells were equilibrated for 2–3 hr in serum-
free EBM-2 medium. Luteal endothelial cells were col-
lected in RLT lysis buffer (guanidine isothiocyante buffer)
from the Qiagen RNeasy kit, and RNA was isolated using
the RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturer's specifications.
RNA isolation and northern analysis
Frozen luteal tissue was homogenized in TRIzol reagent
using a Polytron tissue homogenizer (Brinkman Instru-
ments, Westbury, NY). For extraction of total RNA from
cultured cells, TRIzol reagent was added directly to indi-
vidual culture flasks, and samples from each culture flask
were isolated separately (samples were not pooled). Fol-
lowing tissue homogenization or cell lysis, total cellular
RNA was isolated according to the TRIzol specifications
sheet. The final RNA precipitate was resuspended in
DEPC-treated double-distilled water, and RNA concentra-
tion was determined spectrophotometrically.
Bovine CD80 and CD86 have cDNA sequences have been
described (GenBank accession numbers Y09950 and
AJ291475[40]). Plasmids containing these sequences
were kindly provided by Dr. Keith Parsons (Institute for
Animal Health, Berkshire, UK), and were used to synthe-
size riboprobes. Glyceraldehyde-3-phosphate was used to
normalize signals from CD80 and CD86 in Northern
analysis, and a partial cDNA fragment of bovine dehydro-
genase (GAPDH) was generated by RT-PCR using bovine-
specific primers described previously [41]. This fragment
was inserted into the pGEM-T Easy Vector (Promega), and
the identity confirmed by sequencing. Anti-sense digoxi-
genin-labeled riboprobes were generated using linearized
plasmids, according to the instructions in Roche Molecu-
lar Biochemicals' DIG Nonradioactive Nucleic Acid Labe-
ling and Detection System manual. Corresponding sense
riboprobes were also synthesized and were used as con-
trols to confirm riboprobe specificity.
For Northern analysis, PolyA+ RNA was isolated from total
cellular RNA using the PolyATract mRNA Isolation System
(Promega) according to the manufacturer's specifications.
One microgram of polyA+ RNA was electrophoretically
separated on 1.5% agarose denaturing gels containing 20
mM MOPS, 5 mM sodium acetate, 1 mM EDTA and 0.66
M formaldehyde. Transfer of RNA to Hybond-N+ mem-
branes was carried out using 10 × SSC (1.5 M NaCl, 0.15
M Na3C6H5O7·2H2O). Transfers were allowed to proceed
for approximately 20 hours. Following transfer, mem-
branes were baked at 80°C for 2 hours to crosslink RNA
to the membranes.
Prehybridization and hybridization were performed in a
Hybaid Micro-4 hybridization oven (ThermoHybaid,
Franklin, MA). Membranes were prehybridized at 68°C
for one hour with hybridization core buffer [250 mM
Na2HPO4, 1 mM EDTA, 5% (w/v) SDS, 0.5% (w/v) block-
ing buffer]. Simultaneous hybridization was performed
using either CD80 and G3PDH riboprobes or CD86 and
G3PDH riboprobes. Riboprobes were denatured for 15
minutes at 68°C in 200 μl of hybridization buffer prior to
use in hybridizations. After 1 hour of prehybridization,Reproductive Biology and Endocrinology 2007, 5:5 http://www.rbej.com/content/5/1/5
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buffer was replaced, denatured riboprobes were added,
and hybridization was carried out for 16 hours at 68°C.
Following hybridization, membranes were washed and
bound DIG-labeled riboprobes were detected using alka-
line phosphatase-conjugated anti-DIG Fab fragments
(1:20,000) in concert with chemiluminescent CDP-Star
substrate. Membranes were exposed to Biomax ML film
(Eastman Kodak Co. Rochester, NY) to detect chemilumi-
nescence.
To quantify steady state concentrations of RNA for each
message, densitometry was performed using a PDI 420oe
Scanning Densitometer. The densitometric values (in
arbitrary units) of each band were normalized to the den-
sitometric values of the corresponding G3PDH band, to
correct for loading inconsistencies.
Reverse-transcription polymerase chain reaction
Sequences, annealing conditions, GenBank accession
numbers for corresponding targets, amplicon sizes, and
references [40-43] for primer sequences used in all RT-
PCR are listed in Table 1. Primer sets were tested in luteal
tissue samples to confirm amplification of single bands,
amplified products were cloned and sequenced to con-
firm their identity, prior to use of primers in analysis of
samples.
A semi-quantitative RT-PCR assay was used to determine
steady-state concentrations of CD80 mRNA in cultures of
bovine mixed luteal parenchymal cells treated with LH,
PGF2α and/or TNF-α. Amplification of CD80 and GAPDH
was performed in duplicate parallel reactions. In prelimi-
nary experiments, the number of cycles in which the reac-
tions entered the logarithmic phase of amplification was
determined individually for each primer set by perform-
ing serial reactions with a single sample, incrementally
increasing the number of cycles, and determining empiri-
cally the cycle number at which amplification is in the log-
arithmic phase. In these experiments, G3PDH
amplification was in the logarithmic phase at 25 cycles,
whereas CD80 was in logarithmic phase at 32 cycles.
Reverse transcription was performed on 200 ng of total
RNA for 15 minutes at 42°C using M-MLV reverse tran-
scriptase. Following reverse transcription, thermal cycling
was performed under the following conditions: denatur-
ing, 94°C for 30 seconds; annealing (temperatures listed
in Table 1) for 30 seconds; extension, 72°C for 60 sec-
onds. Following amplification, PCR products were sepa-
rated on 1.5% agarose gels and visualized with ethidium
bromide. Densitometric values (in arbitrary densitometric
units) of CD80 bands were normalized to values of corre-
sponding G3PDH bands prior to statistical analysis.
Steady-state concentrations of CD86 mRNA in cultures of
mixed luteal parenchymal cells treated with LH, PGF2α
and/or TNF-α were determined by quantitative PCR anal-
ysis using a Roche LightCycler real-time PCR thermal
cycler. Reverse transcription on 200 ng of total cellular
RNA, as described above for semi-quantitative RT-PCR.
Quantitative PCR was then performed using 40 ng of
reverse transcribed total RNA, with the Roche FastStart
DNA Master SYBR Green I kit according to the manufac-
turer's instructions. Ramping speed for transition from
denaturing to annealing steps and from annealing to
extension step was slowed to 1°/sec to mimic conditions
in a block-type thermal cycler, while ramping speed from
extension to denaturing steps was set at 20°/sec to mini-
mize total running time. Thermal cycling was carried out
using the following conditions: denaturing, 94°C for 30
seconds; annealing (temperatures listed in Table 1) for 30
seconds; extension, 72°C for 60 seconds, 40 cycles total.
As a standard curve, the bovine CD86 insert provided by
Dr. Keith Parsons was removed from the pCDNA3 vector
by digestion with BamHI and EcoRI. The insert was elec-
trophoretically separated, eluted from the gel, and the
concentration of insert DNA was determined spectropho-
tometrically. The CD86 insert was then used to prepare
serial dilutions to be used as an external standard curve in
the quantitative PCR assays. Melting curve analysis per-
formed during validation of the primers revealed the pres-
Table 1: 
Target Primer Sequence Amplicon Size Annealing Temp (°C) GenBank Accession no. Reference
CD80 Forward: 5'-GAACCGCACCATCACTGACA-3'
Reverse: 5'-TAATGGTCCAGGTCAGGTGC-3'
485 bp 56°C Y09950 [40]
CD86 Forward: 5'-GACCTTGAGACTCCACAACG-3'
Reverse: 5'-GTAGAGCTGCAATCCAGAGG-3'
490 bp 58°C AJ291475 -
CD31 Forward: 5'-GTTCAGCGAAGTTCTGCGAG-3'
Reverse: 5'-CTTGCTGGCTGTGGTCTTGT-3'
229 bp 58°C U35433 [43]
GAPDH Forward: 5'-AAGATTGTCAGCAATGCC-3'
Reverse: 5'-ACAGACACGTTGGGAG-3'
293 bp 56°C BC102589 -
GAPDH Forward: 5'-TGTTCCAGTATGATTCCACCC-3'
Reverse: 5'-TCCACCACCCTGTTGCTGTA-3'
854 bp 58°C NM_001034034 [41]
StAR Forward: 5'-CCTCTCTACAGCGACCAA-3'
Reverse: 5'-TCGTGAGTGATGACCGTG-3'
311 bp 58°C Y17259 [42]Reproductive Biology and Endocrinology 2007, 5:5 http://www.rbej.com/content/5/1/5
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ence of a minor primer dimer product in the CD86
amplification reactions, with a melting temperature of
approximately 75°C. Therefore, fluorescence was meas-
ured in both samples and standards at 77°C, to denature
primer dimer products and eliminate any fluorescence
due to binding of SYBR Green to these undesired prod-
ucts. Fluorescence values were measured in each reaction
at the end of each cycle using the single acquisition mode.
A melting curve analysis was performed after the end of
the last cycle in order to verify the amplification of a single
product in each sample. Samples were run in duplicate
and fluorescence values for duplicate samples were aver-
aged. The baseline fluorescence reading and noise band
cut-off were set manually for samples and standards, in
order to eliminate background fluorescence values from
calculation of the slope and y-intercept of the standard
curve. GAPDH was amplified in duplicate parallel reac-
tions, and the average of the duplicate CD86 values from
each sample was normalized to the corresponding average
of the duplicate GAPDH values for each sample. A stand-
ard curve was generated using average fluorescence values
of duplicate standards, and average fluorescence values of
samples were then used to calculate the concentration of
CD86 mRNA in each sample, using the Fit Points meth-
ods of the accompanying Light Cycler Data Analysis soft-
ware.
Steady-state concentrations of mRNA encoding StAR,
CD31, CD80, CD86 and GAPDH were determined in
total RNA extracted from cultures of mixed luteal paren-
chymal cells and luteal endothelial cells, using an MJ
Research Opticon 2 real-time PCR thermal cycler. StAR (a
marker for steroidogenic cells) and CD31 (a marker for
endothelial cells) mRNAs were amplified as a means to
assess the composition of cultures of mixed luteal paren-
chymal cells and luteal endothelial cells. Prior to PCR,
reverse transcription using random hexamer primers was
performed on 2 μg of total RNA extracted from cultures.
PCR was then performed, using 200 ng of reverse tran-
scribed cDNA, using the DyNAmo™ HS SYBR Green qPCR
kit according to the manufacturer's instructions. Thermal
cycling was carried out using the following conditions:
denaturation, 94°C for 30 seconds; annealing, (tempera-
tures listed in Table 1) for 30 seconds; extension, 72°C for
60 seconds, for a total of 32 cycles. Melting curve analysis
was performed after the end of the last cycle, and in con-
junction with gel electrophoresis of amplified products,
was used to verify the amplification of a single product in
each sample. Fluorescence values in each tube were meas-
ured at the end of each cycle using single acquisition
mode. Fluorescence values of the product of interest in
each sample were standardized to the corresponding
GAPDH fluorescence values, and these standardized val-
ues were then used to calculate the mean steady-state
amounts of each message. Since no standard curve was
run for the messages of interest, values were expressed in
arbitrary units of fluorescence for purposes of analysis.
Isolation of T lymphocytes
Isolation of T lymphocytes from whole blood was per-
formed as described previously [22]. Briefly, blood was
collected from cows via jugular venipuncture at the time
of CL removal. Acid citrate dextrose (ACD) solution (41.6
mM citric acid, 74.8 mM sodium citrate, 136 mM dex-
trose) was used to prevent coagulation of whole blood (15
ml of ACD per 85 ml of whole blood). Anticoagulated
whole blood was centrifuged, white blood cell layers were
collected and centrifuged through Ficoll-Hypaque to iso-
late peripheral blood mononuclear cells (PBMC). T lym-
phocytes were separated from PBMC by depletion of class
II MHC-positive cells using the mouse anti-bovine mono-
clonal antibodies TH14B, TH81A5, and H42A (VMRD,
Pullman, WA) in conjunction with the MACS Cell Separa-
tion System (Miltenyi Biotec, Inc. Auburn, CA). This sep-
aration procedure yielded a population of cells that is
approximately 96% positive for CD3 (as determined by
indirect immunofluorescence using anti-CD3 antibody
MM1A [VMRD]).
Co-culture of luteal cells and T lymphocytes
Co-culture of mixed luteal parenchymal cells and T cells
was performed as described previously [21,22]. Briefly,
mixed luteal parenchymal cells were treated with 50 μg/
ml mitomycin C to prevent proliferation of the cells in
culture, and 3.2 × 104 mixed luteal parenchymal cells were
placed in culture with 1.0 × 105 T lymphocytes in 96-well
plates (Corning, Corning, NY). Cultures were performed
in RPMI 1640 containing 10% heat-inactivated fetal calf
serum, 25 mM HEPES, 2 mM L-glutamine, 100 IU penicil-
lin and 100 μg/ml streptomycin in the presence of 1 μg/
ml staphylococcal enterotoxin B (SEB). T lymphocytes
were also cultured with mitomycin C-treated PBMCs,
which contain antigen presenting cells such as monocytes
and B lymphocytes. These cultures served as a positive
control to determine the effects of antibody treatments.
To determine the importance of costimulation to the acti-
vation of T lymphocytes by bovine mixed luteal parenchy-
mal cells, co-cultures were treated with monoclonal
antibodies raised against bovine CD80 or CD86. Antibod-
ies (murine ascites fluid diluted 1:10 with PBS containing
0.1% NaN3) were the generous gift of Dr. Keith Parsons,
and were dialyzed exhaustively against PBS using Slide-A-
Lyzer dialysis cassettes (Pierce, Rockford, IL). Dialyzed
antibodies were added to co-cultures at a final treatment
concentration equivalent to a 1:1000 dilution of ascites
fluid.
All co-cultures were performed in a humidified atmos-
phere of 5% CO2 in air at 37°C for 72 hours. During theReproductive Biology and Endocrinology 2007, 5:5 http://www.rbej.com/content/5/1/5
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last 6 hours of culture, 0.5 μCi 3H-thymidine was added
to each well to measure cellular proliferation. At the end
of the 72 hour culture period, culture plates were frozen at
-80°C. Cells were subsequently harvested using a semi-
automatic cell harvester (Skatron Instruments, Sterling,
VA) and incorporation of 3H-thymidine into the cellular
DNA was determined by scintillation counting.
Statistical analysis
For Northern analyses, differences in normalized densito-
metric values of CD80 and CD86 mRNA between stages
of the estrous cycle and following administration of
PGF2α were determined using one-way analysis of vari-
ance. Similarly, for semi-quantitative RT-PCR analysis of
CD80 mRNA in cultured cells, normalized densitometric
values of CD80 cDNA were subjected to one-way ANOVA
to determine whether differences existed between culture
treatment means. Relative differences in steady-state con-
centrations of CD31, StAR, CD80 and CD86 mRNA
between cultures of mixed luteal parenchymal cells or
luteal endothelial cells were determined using Student's T-
test. Steady-state concentrations of CD86 mRNA in cul-
tures of mixed luteal parenchymal cells treated with LH,
PGF2α and/or TNF-α determined by quantitative RT-PCR
analyses were subjected to one-way ANOVA to determine
if differences existed between culture treatment means. In
all ANOVA analyses, the Student-Newman-Keuls (SNK)
test was used to determine differences between specific
means. Differences in mean cell counts from co-culture
experiments were also determined using one-way
ANOVA, and the SNK test was used to determine differ-
ences between specific means. Means were considered sig-
nificantly different at p < 0.05. Statistical analyses were
performed using the SigmaStat statistical analysis software
package (Jandel Corporation, San Rafael, CA).
Results
Northern analysis revealed the presence of CD80 and
CD86 mRNA in luteal tissue throughout the estrous cycle
and at all time points during PGF2α-induced luteal regres-
sion. In these studies, lymph node tissue, which contains
antigen-presenting cells such as macrophages, dendritic
cells and B lymphocytes, was used as a source of positive
control RNA. Muscle tissue was used as a source of nega-
tive control RNA. Figure 1 displays the results of Northern
analysis of CD80 mRNA in luteal tissue. A single band
representing a transcript of approximately 3.0 Kb was
present in positive control RNA, and a corresponding
band was also present in all luteal tissue samples (Figure
1a). Muscle tissue RNA, which served as a negative con-
trol, was devoid of any transcript. Mean densitometric val-
ues representing steady-state concentrations of CD80
mRNA in the CL (n = 4 CL per time point) are displayed
in Figure 1b. Steady-state concentrations of CD80 mRNA
were not significantly different (p > 0.05), but tended to
be greater (p = 0.74) in CL collected at midcycle compared
with CL collected either early or late in the estrous cycle
(Figure 1b). There were no changes in CD80 mRNA con-
centrations in response to administration of PGF2α to the
cow (p > 0.10).
Results of Northern analysis of CD86 mRNA in luteal tis-
sue are displayed in Figure 2. A single band representing a
transcript of approximately 3.1 Kb was present in RNA
from lymph node tissue. A corresponding band was also
present in RNA from luteal tissue (Figure 2a). There was a
second, less abundant band of greater size present in
luteal tissue, to which there was no corresponding band in
positive control RNA. Since there are no reports in the lit-
erature of a second larger transcript of CD86 and we are
uncertain of the identity of this band, it was excluded
from analyses. Muscle tissue RNA (negative control) was
devoid of any transcript. Figure 2b depicts densitometric
values representing the mean steady-state concentrations
of CD86 mRNA in the CL (n = 4 CL per time point). In CL
collected during the estrous cycle, highest concentrations
of CD86 mRNA were present in midcycle CL (p < 0.05) as
compared to early or late CL. Similar to CD80 mRNA, in
vivo administration of PGF2α did not affect the concentra-
tions of CD86 mRNA present in luteal tissue (p > 0.10).
To address the possibility that endothelial cells of the CL
express costimulatory molecules, the presence and steady-
state concentrations of CD80 and CD86 mRNA were
assessed in cultures of highly enriched luteal endothelial
cells. To determine the composition and purity of the
mixed luteal parenchymal cell and luteal endothelial cell
cultures, quantitative RT-PCR to determine steady-state
concentrations of CD31 (an endothelial cell adhesion
molecule) and steroidogenic acute regulatory protein
(StAR) mRNAs was performed. Concentrations of CD31
mRNA were approximately 10-fold greater (p > 0.05) in
cultures of luteal endothelial cells compared with mixed
luteal parenchymal cell cultures (data not shown). StAR
mRNA was undetectable in some luteal endothelial cul-
tures, and was present in concentrations near the detec-
tion limit of the PCR assay in others, but was present in
high concentrations in cultures of mixed luteal parenchy-
mal cells (data not shown). CD80 and CD86 mRNA was
present and easily detectable by quantitative RT-PCR in
mixed luteal parenchymal cell cultures (Figure 3a). In
contrast, only CD80 mRNA was present in luteal endothe-
lial cell cultures (Figure 3b), but steady-state concentra-
tions of CD80 mRNA were much less in luteal endothelial
cell cultures compared with mixed luteal parenchymal cell
cultures (data not shown).
To examine the regulation of costimulatory molecule
expression, cultures of mixed luteal parenchymal cells
were treated with 10 ng/ml LH, 10 ng/ml PGF2α, or 50 ng/Reproductive Biology and Endocrinology 2007, 5:5 http://www.rbej.com/content/5/1/5
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ml TNF-α, and all possible combinations of each. Due to
the limited amount of total RNA isolated from individual
cultures, RT-PCR analysis was used to examine relative
steady-state concentrations of CD80 and CD86 mRNA in
cultures of mixed luteal parenchymal cells. We wished to
use quantitative real-time RT-PCR (RT-qPCR) to measure
both transcripts, however we were unable to develop a
working primer set corresponding to CD80 for use in the
Roche LightCycler. Therefore, semi-quantitative RT-PCR
was used to determine steady-state concentrations of
CD80 mRNA in mixed luteal parenchymal cell cultures,
whereas RT-qPCR was used to determine concentrations
of CD86 mRNA. Analysis of steady-state concentrations of
CD80 mRNA revealed the presence of a 485 bp amplified
product corresponding to CD80 mRNA in all mixed luteal
parenchymal cell cultures (not shown). There were no
changes in relative concentrations of CD80 mRNA associ-
ated with any treatments used in this study (Figure 4a).
Similarly, RT-qPCR analysis showed no changes in steady-
state concentrations of CD86 mRNA in cultures of mixed
luteal parenchymal cells, regardless of treatment (Figure
4b).
T lymphocyte proliferation assays were performed to
determine whether costimulatory molecules were func-
tional participants in interactions between mixed luteal
parenchymal cells and T cells in vitro. The results of this
experiment are depicted in Figure 5. T cell proliferation (as
measured by 3H-thymidine incorporation) in co-cultures
of mixed luteal parenchymal cells and T lymphocytes was
Northern analysis of CD80 and bovine luteal tissue Figure 1
Northern analysis of CD80 and bovine luteal tissue. A) Representative Northern blot of CD80 mRNA and corresponding 
G3PDH mRNA in luteal tissue samples collected early, during midcycle, or late in the estrous cycle, and at 0, 0.5, 1, 4, 12 or 24 
hours following administration of PGF2α. Muscle tissue RNA served as a negative control, and lymph node RNA served as a 
positive control. B) Steady-state concentrations of CD80 mRNA in luteal tissue. Bars represent densitometric values of CD80 
mRNA normalized to G3PDH mRNA detected by Northern analysis (n = 4 CL at each time point). Values with different let-
ters tended to be different (p = 0.074).
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inhibited in the presence of anti-CD80 or anti-CD86
monoclonal antibody alone (p < 0.05), and T cell prolif-
eration was further inhibited when both antibodies were
used in combination (p < 0.05). Addition of anti-CD80 or
anti-CD86 to cultures containing PBMCs (which contain
antigen presenting cells such as monocytes/macrophages
and B cells) and T lymphocytes had a similar effect.
Discussion
To the best of our knowledge this study is the first in
which expression of CD80 and CD86 in luteal tissue of
any species has been reported. We have also demonstrated
in this study that cells of the corpus luteum express func-
tional costimulatory molecules that facilitate interactions
between luteal parenchymal cells and T lymphocytes,
enhancing the ability of mixed luteal parenchymal cells to
stimulate T lymphocyte activation (as measured by prolif-
eration) in vitro. Northern analyses revealed that the great-
est steady-state concentrations of mRNA for both
costimulatory molecules are present in luteal tissue at
midcycle. Macrophages present in luteal tissue are likely
to be one source of costimulatory molecule mRNA in the
CL, since these cell types express costimulatory molecules
[44,45]. In the cow, the number of macrophages present
in the CL is higher during the mid (day 12 post-estrus)
and late (day 18 post-estrus) luteal phase compared with
the early luteal phase (day 6 post-estrus) [6]. Northern
analysis in the present study revealed a similar trend with
A) Representative Northern blot of CD86 mRNA and corresponding G3PDH mRNA in luteal tissue samples collected early,  during midcycle, or late in the estrous cycle, and at 0, 0.5, 1, 4, 12 or 24 hours following administration of PGF2α Figure 2
A) Representative Northern blot of CD86 mRNA and corresponding G3PDH mRNA in luteal tissue samples collected early, 
during midcycle, or late in the estrous cycle, and at 0, 0.5, 1, 4, 12 or 24 hours following administration of PGF2α. Muscle tissue 
RNA served as a negative control, and lymph node RNA served as a positive control. B) Steady-state concentrations of CD86 
mRNA in luteal tissue. Bars represent densitometric values of CD86 mRNA normalized to G3PDH mRNA detected by North-
ern analysis (n = 4 CL at each time point). Different letters indicate significant differences (p < 0.05).
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regard to concentrations of CD80 and CD86 mRNA in
luteal tissue collected during the early and mid luteal
phase.
In addition, CD80 mRNA, but not CD86 mRNA, was
found in cultures of highly enriched luteal endothelial
cells. With regard to the luteal endothelial cell cultures
used in the present study, these cultures appear almost
completely devoid of luteal cells expressing StAR (ster-
oidogenic luteal cells). The concentration of mRNA
encoding the endothelial cell adhesion molecule CD31 in
luteal endothelial cell cultures was approximately 10-fold
greater than in mixed luteal parenchymal cell cultures,
whereas StAR mRNA was nearly undetectable. The mixed
luteal parenchymal cell cultures used in the present study
contain largely steroidogenic cells, but are likely to also
contain small numbers of endothelial cells; StAR mRNA
was abundant in the mixed luteal parenchymal cell cul-
tures, but concentrations of CD31 mRNA were much less
than those in luteal endothelial cell cultures. It is possible
that significant numbers of macrophages are present in
mixed luteal parenchymal cell cultures, and these cells
could account for the greater concentration of CD80
mRNA present in mixed luteal parenchymal cell cultures
compared with luteal endothelial cell cultures, as well as
the presence of CD86 mRNA in mixed luteal parenchymal
cell cultures but not in luteal endothelial cell cultures. It
seems unlikely that macrophages are present in the luteal
endothelial cell cultures, due to the purification proce-
dures used to derive these cultures. However, the possibil-
ity that a small number of contaminating macrophages
are the source of CD80 mRNA detected in these cultures
by RT-PCR cannot be excluded. The absence of CD86
mRNA and very low amounts of CD80 mRNA were unex-
pected and surprising, since we have detected high con-
centrations of mRNA for class II MHC molecules in luteal
endothelial cell cells (Cannon et al., unpublished). A pure
population of steroidogenic luteal cells (ie cells free of
macrophages and endothelial cells) could not be
obtained, and therefore it is not possible to conclude from
the present studies whether or not steroidogenic luteal
cells express CD80 and CD86. However, it is evident from
this portion of the study that endothelial cells of the cor-
pus luteum do not express CD86. Luteal endothelial cells
may express CD80, but the possibility that small numbers
PCR analysis of regulation of CD80 and CD86 expression in  cultured luteal cells Figure 4
PCR analysis of regulation of CD80 and CD86 expression in 
cultured luteal cells. Bars represent steady-state concentra-
tions of CD80 and CD86 mRNA in cultured bovine luteal 
cells treated with LH (10 ng/ml), PGF2α (10 ng/ml), and/or 
TNF-α (50 ng/ml). A) Bars represent densitometric values of 
amplified CD80 mRNA products, standardized to G3PDH, as 
detected by semi-quantitative RT-PCR analysis. There were 
no significant differences (p > 0.10; n = 4). B) Bars represent 
CD86 cDNA concentrations, as determined by RT-qPCR 
analysis. There were no significant differences (p > 0.10; n = 
4).
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of contaminating macrophages are the source of CD80
mRNA in luteal endothelial cell cultures cannot be ruled
out at this time.
The in vitro co-culture experiments performed in this study
demonstrate that costimulatory molecules are expressed
on cells of the bovine CL are functional, since antibodies
against these cell surface proteins inhibit luteal parenchy-
mal cell-stimulated T cell proliferation. Culture medium
containing 10% fetal bovine serum is employed in these
experiments in conjunction with mixed luteal parenchy-
mal cells. Despite routine precautions taken during the
dissociation procedure to minimize the presence of
endothelial cells and macrophages, it is possible that, in
addition to steroidogenic luteal cells, these cell types are
also present in the co-cultures of mixed luteal parenchy-
mal cells and T cells. We have demonstrated that CD80
mRNA is present in cultured luteal endothelial cells, but
we have been unable to determine immunohistochemi-
cally the identity of the cells within the CL that express
CD80 and CD86. The monoclonal anti-bovine CD80 and
CD86 antibodies used in our co-culture experiments were
not able to detect costimulatory molecules in control tis-
sues (lymph node, spleen and liver tissue) or luteal tissue.
Additionally, polyclonal anti-human anti-CD80 and anti-
CD86 antisera available commercially from R&D systems
were employed in further attempts to identify the cells
expressing costimulatory molecules, without success.
Luteinizing hormone, PGF2α and TNF-α, affect progester-
one secretion by cultured bovine mixed luteal parenchy-
mal cells [15,34]. In addition, TNF-α has been shown to
stimulate prostaglandin production in cultured bovine
mixed luteal parenchymal cells [15,16] and also affects
viability and gene expression in cultured bovine mixed
luteal parenchymal cells [35,36]. However, LH, PGF2α and
TNF-α, individually or in combination, were without
effect on steady-state concentrations of CD80 and CD86
mRNA in cultured bovine mixed luteal parenchymal cells.
Though initially interpreted as a negative result, these
results may provide a subtle clue to the identity of cells
expressing costimulatory molecules in the CL. Given the
lack of effect of these known modulators of luteal paren-
chymal cell function on steady-state concentrations of
costimulatory molecule mRNA in mixed luteal parenchy-
mal cell cultures, one possible interpretation of these
results is that the luteal parenchymal cells do not express
costimulatory molecules. However, it is equally plausible
that luteal parenchymal cells express costimulatory mole-
cules, but that expression is simply not regulated by LH,
PGF2α or TNF-α. Future studies are needed to conclusively
determine whether bovine luteal parenchymal cells
express costimulatory molecules.
A costimulatory signal is necessary for antigen presenting
cells to induce activation and proliferation of T cells [30-
32]. To determine whether functional costimulatory mol-
ecules are expressed on luteal parenchymal cells, T lym-
phocyte proliferation assays were performed in which
freshly dissociated mixed luteal parenchymal cells from
midcycle CL were placed in co-culture with T lym-
phocytes, as previously described [21,22]. In addition,
PBMCs served as a control antigen presenting cell popula-
tion in these studies, since monocytes/macrophages and B
cells that express costimulatory molecules are present in
PBMCs. Studies using antigen presenting cell lines have
demonstrated that antibodies that bind to costimulatory
molecules can interfere with costimulation and inhibit
MHC-dependent T lymphocyte proliferation stimulated
by antigen presenting cells in vitro [46-48]. In the present
study, anti-bovine CD80 and anti-bovine CD86 mAbs
inhibited mixed luteal parenchymal cell-stimulated T
lymphocyte proliferation, and both antibodies used in
combination exerted an inhibitory effect that appeared to
be additive. Using a B cell lymphoma line Chen and cow-
orkers [49] observed a similar effect, as was the case in the
present study when PBMCs were used as antigen present-
ing cells. Therefore it can be concluded that the costimu-
latory molecules expressed by cells of the bovine corpus
luteum are functional.
Effects of anti-CD80 and anti-CD86 antibodies on luteal cell- stimulated T lymphocyte proliferation Figure 5
Effects of anti-CD80 and anti-CD86 antibodies on luteal cell-
stimulated T lymphocyte proliferation. Bars represent T lym-
phocyte proliferation (as measured by H3-thymidine incorpo-
ration) in co-cultures of luteal cells and T lymphocytes (black 
bars) or PBMCs and T lymphocytes (gray bars), in the 
absence or presence of anti-CD80 or anti-CD86 mAbs. Dif-
ference superscripts represent significant differences (n = 4; 
p < 0.05).
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Cells within the bovine CL express both classes of MHC
molecules. The presence of class I and class II MHC mole-
cules on the surface of a cell allows the cell to interact with
CD8+ and CD4+ T lymphocytes, respectively. In the cow,
expression of class I MHC molecules does not vary with
stage of the estrous cycle. Cells positive for class II MHC
molecules are nearly undetectable in early CL, but expres-
sion increases by midcycle [20], indicating induction of
class II expression that may coincide with the acquisition
of luteolytic capacity. Further, numbers of cells positive
for class II MHC molecules, and degree of class II expres-
sion by positive cells, both increase near the time of luteal
regression, but are lower in pregnant compared to non-
pregnant animals [20]. This pattern of expression suggests
the involvement of MHC molecules in a mechanism that
facilitates luteal regression. In this context, it is enigmatic
that expression of costimulatory molecules is greatest dur-
ing midcycle and declines near the time of luteal regres-
sion. It is possible that steady-state concentrations of
mRNA for CD80 and CD86 are greatest during midcycle,
but that protein concentrations are elevated toward the
end of the estrous cycle. From the present studies it is not
possible to draw conclusion about temporal expression of
the cell surface proteins, but expression of functional cos-
timulatory molecules on parenchymal cells isolated from
midcycle CL has been conclusively demonstrated. It can
therefore be inferred from the data from this and other
studies that parenchymal cells from fully functional, mid-
luteal phase bovine CL posses the capacity to stimulate T
lymphocyte activation [21,22], due to expression of both
class II MHC molecules [20] and expression of costimula-
tory molecules (present study). If MHC-mediated activa-
tion of T lymphocytes plays a role in luteal regression, it
seems confounding that mixed luteal parenchymal cells
from midcycle CL are able to stimulate proliferation of T
lymphocytes. However, in a previous study we demon-
strated that progesterone, which is present in very high
concentrations in midcycle luteal tissue, inhibits luteal
parenchymal cell-stimulated T lymphocyte proliferation
[22]. The ability of cells within the CL to stimulate the
activation of T lymphocytes may thus be attenuated by
mediators present within the luteal microenvironment,
modulating the activity of the lymphocytes in a manner
dependent on the stage of the estrous cycle.
Conclusion
This study demonstrates the presence of mRNA encoding
the molecules CD80 and CD86 in bovine luteal tissue, as
well as the presence of functional costimulatory mole-
cules on luteal parenchymal cells. Costimulatory mole-
cule mRNA is highest during midcycle, at a time when the
CL is fully functional and progesterone production is
maximal. Low concentrations of CD80 mRNA were found
in luteal endothelial cell cultures, indicating that luteal
endothelial cells may be a source of CD80 mRNA in the
bovine CL, but contaminating macrophages cannot be
ruled out as a source of CD80 mRNA in these cultures.
Given the pattern of expression of costimulatory mole-
cules in the CL, it seems unlikely that these molecules are
involved in the process of luteal regression. However, the
absence of costimulatory molecules on luteal endothelial
cells expressing class II MHC antigens could provide a
mechanism for inducing anergy in infiltrating T cells,
thereby maintaining tolerance to the CL. Further studies
are needed to examine the outcome of interactions
between the various types of luteal parenchymal cells
(steroidogenic, endothelial) and T lymphocytes, to deter-
mine how these interactions modulate T cell function.
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